ARGX:NSD-argenx NV ADR (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 384.37

Change

-1.17 (-0.30)%

Market Cap

USD 21.32B

Volume

0.23M

Avg Analyst Target

USD 442.00 (+14.99%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ARGX Stock Forecast & Price:
Based on the argenx NV ADR stock forecasts from 15 analysts, the average analyst target price for argenx NV ADR is USD 442.00 over the next 12 months. argenx NV ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of argenx NV ADR is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, argenx NV ADR’s stock price was USD 384.37. argenx NV ADR’s stock price has changed by -3.42% over the past week, +6.09% over the past month and +31.40% over the last year.

About argenx NV ADR (ARGX:NSD)

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients wi ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+16.80 (+2.25%)

USD83.46B 192.56 12.35
VRTX Vertex Pharmaceuticals Inc

+5.77 (+1.85%)

USD82.49B 25.21 17.39
MRNA Moderna Inc

+5.46 (+3.15%)

USD67.59B 6.10 4.60
BNTX BioNTech SE

+1.01 (+0.62%)

USD41.19B 3.97 1.87
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
GMAB Genmab AS

+0.43 (+0.95%)

USD31.54B 37.65 3.71
ALNY Alnylam Pharmaceuticals Inc

+11.69 (+5.32%)

USD27.02B N/A -29.83
SGEN Seagen Inc

+1.45 (+1.23%)

USD22.73B 55.02 -38.32
BGNE BeiGene Ltd

+5.80 (+3.09%)

USD21.81B N/A -8.80
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ARGX

Symbol Name Weight Mer Price(Change) Market Cap
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

+0.31 (+2.11%)

USD0.02B
EWK iShares MSCI Belgium ETF 0.00 % 0.50 %

+0.05 (+0.28%)

USD0.01B
RYJ Invesco Raymond James SB-.. 0.00 % 0.81 %

-0.04 (-0.07%)

USD0.12B
EXSD:F iShares STOXX Europe Mid .. 0.00 % 0.20 %

-0.33 (-0.71%)

USD0.20B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.76% 88% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.76% 88% B+ 90% A-
Trailing 12 Months  
Capital Gain 24.19% 92% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.19% 91% A- 94% A
Trailing 5 Years  
Capital Gain 1,162.30% 96% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,162.30% 96% A 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 46.95% 89% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.95% 89% B+ 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 38.84% 59% F 39% F
Risk Adjusted Return 120.85% 100% A+ 100% A+
Market Capitalization 21.32B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.49 15% F 12% F
Price / Cash Flow Ratio -35.14 94% A 79% C+
EV/EBITDA -22.20 97% A+ 88% B+
Management Effectiveness  
Return on Equity -30.64% 79% C+ 38% F
Return on Invested Capital -16.96% 81% B- 37% F
Return on Assets -16.49% 80% B- 29% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.30 66% D 54% F
Short Percent 1.93% 63% D 53% F
Beta 0.65 74% C 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector